There are many ways in which our cognitive ability can be reduced or damaged, whether through aging, genetics, traumatic injury, or any number of other factors

do not add cannabis to the treatment plan.What Better Evidence Would NeedStronger research would follow patients over time with repeated dosing, track mood and psychosis outcomes alongside cognition, and test whether the acute timing effect persists or fades with regular use.It would also need to identify which patients, if any, show a genuine cognitive benefit versus those for whom cannabis use carries more risk than benefit.Lens takeawayLongitudinal, safety-inclusive research is the next necessary step.Nuance Belongs in Public MessagingPublic and patient-facing messaging about cannabis and bipolar disorder should reflect that this is an early, mixed-design signal, not an endorsement of cannabis as a cognitive treatment.Overstating this finding risks encouraging unsupervised use in a population that already carries elevated risk from cannabis-related mood and psychotic symptoms.Lens takeawayHonest uncertainty protects patients better than an oversimplified headline

Tirzepatide may not be suitable for everyone
Access this article Similar content being viewed by others References Swinburn BA, Kraak VI, Allender S, Atkins VJ, Baker PI, Bogard JR, et al
Effective treatment of cobalamin deficiency with oral cobalamin
In most cases, pain medication is prescribed for about 3-5 days to reduce any discomfort following the surgery